Bioventus Inc.

Bioventus Inc. (BVS) priced its initial public offering on Feb 12, 2021 at $13.00 per share, below its $16.00–$18.00 range, raising $104M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $723.1M. Morgan Stanley was lead-left underwriter, joined by J.P. Morgan, Goldman Sachs and Canaccord Genuity. Latham & Watkins advised the company and Simpson Thacher advised the underwriters.

Bioventus Inc. is a global medical device company developing and selling minimally invasive treatments that support the body's natural healing process. Its non-invasive devices and biologics address osteoarthritic joint pain and joint preservation, spinal fusion surgery and bone fractures.

Status

IPO

Ticker

BVS

Exchange

Nasdaq Global Select

Priced

Feb 12, 2021

IPO price

$13.00

Price range

$16.00–$18.00

Raised

$104M

Market cap at IPO price

$723.1M

First filed

Jun 30, 2016

Underwriters

Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity

Company counsel

Latham & Watkins

Underwriters' counsel

Simpson Thacher

Sector

Healthcare

Country / state

NC

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.